Objectives:To compare the direct medical costs and services by point of service (PoS) and the prescription drug (Rx) costs and services for persons with Hepatitis-C (HCV) who are treated (HCV-Tx) and not-treated (HCV-noTx).
This study reported the following significant (P < 0.0001) findings:
Ø HCV employees had higher mean annual medical costs ($3,012) than control employees ($1,265) in all point-of-service categories Ø The annual prescription drug (Rx) cost for employees with HCV and the control cohort were $4,932 and $600, respectively.
Background
• To compare the direct medical costs and services by point of service (PoS) and the prescription drug (Rx) costs and prescriptions among persons with Hepatitis-C (HCV) who are treated (HCV-Tx) and not-treated (HCV-noTx).
Objectives
• A retrospective analysis using the HCMS Research Reference Database, which represents multiple US-based employers and contained employee data from 2001-2Q2007.
• This analysis compared the annual direct medical costs and services for healthcare by PoS, and Rx costs and prescriptions for HCV employees with and without treatment.
• Incremental costs and services were calculated (Treated minus Untreated).
• ICD-9 Codes were used to identify employees with HCV. All subjects were required to have at least 1 month of eligibility.
• Index dates were assigned for all subjects and defined as: Ø The date of the first ribavirin, interferon or peginterferon Rx (for the HCV-Tx cohort).
Ø The average index date (by company) of the HCV-Tx cohort (for the HCV-noTx cohort).
• Two-part regression models were used to compare the cohorts, adjusting for demographics, job-related variables, eligibility months, and Charlson Comorbidity Index. 4 • PoS Locations include: doctors office (MD), inpatient hospital (IN), outpatient hospital or clinic (OUT), emergency department (ED), laboratory (LAB), and other.
• Annual direct Rx costs and prescriptions were also calculated.
• All costs were inflated to 2010 US$.
Methods
• Current treatments for HCV cost $22,726 per year in drug therapy (16 times higher than drug costs of non-treated employees).
• Higher costs associated with HCV Treatment in the doctors' office were offset by lower costs from hospitalizations and the use of outpatient clinics. 
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